Session

IBD (Posters)

FIRST SUCCESSFUL COMPARISON OF QUANTUM BLUE® RAPID TDM ASSAY STANDARDIZATION WITH WHO INTERNATIONAL STANDARD FOR INFLIXIMAB
FIRST SUCCESSFUL COMPARISON OF QUANTUM BLUE® RAPID TDM ASSAY STANDARDIZATION WITH WHO INTERNATIONAL STANDARD FOR INFLIXIMAB

IBD (Posters)  et al.

SAFETY AND EFFICACY OF USTEKINUMAB FOR CROHN'S DISEASE (CD): THE CROSS PENNINE EXPERIENCE
SAFETY AND EFFICACY OF USTEKINUMAB FOR CROHN'S DISEASE (CD): THE CROSS PENNINE EXPERIENCE

IBD (Posters)  et al.

NO BENEFIT OF CONCOMITANT IMMUNOMODULATOR THERAPY ON EFFICACY OF NON - ANTI-TNF BIOLOGICS IN INFLAMMATORY BOWEL DISEASES: A META-ANALYSIS
NO BENEFIT OF CONCOMITANT IMMUNOMODULATOR THERAPY ON EFFICACY OF NON - ANTI-TNF BIOLOGICS IN INFLAMMATORY BOWEL DISEASES: A META-ANALYSIS

IBD (Posters)  et al.

TREATMENT PATTERNS OF COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN: THE PREFACE STUDY, A RETROSPECTIVE CHART REVIEW
TREATMENT PATTERNS OF COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN: THE PREFACE STUDY, A RETROSPECTIVE CHART REVIEW

IBD (Posters)  et al.

EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS
EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS

IBD (Posters)  et al.

LOW ADHESION TO LATENT TUBERCULOSIS (TB) SCREENING RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS: RESULTS OF THE INFEII REGISTRY OF GETECCU
LOW ADHESION TO LATENT TUBERCULOSIS (TB) SCREENING RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS: RESULTS OF THE INFEII REGISTRY OF GETECCU

IBD (Posters)  et al.

CHARACTERISTICS OF ULCERATIVE COLITIS PATIENTS BY URGENCY OF DEFECATION AT ENROLLMENT IN THE CORRONA INFLAMMATORY BOWEL DISEASE REGISTRY
CHARACTERISTICS OF ULCERATIVE COLITIS PATIENTS BY URGENCY OF DEFECATION AT ENROLLMENT IN THE CORRONA INFLAMMATORY BOWEL DISEASE REGISTRY

IBD (Posters)  et al.

IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS
IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS

IBD (Posters)  et al.

THE ASSOCIATION BETWEEN PATIENT ACTIVATION AND HEALTH-RELATED QUALITY OF LIFE AMONG INDIVIDUALS WITH CROHN'S DISEASE
THE ASSOCIATION BETWEEN PATIENT ACTIVATION AND HEALTH-RELATED QUALITY OF LIFE AMONG INDIVIDUALS WITH CROHN'S DISEASE

IBD (Posters)  et al.

OCCURRENCE OF COLORECTAL CANCER AND THE EFFECT OF MEDICAL TREATMENT IN CROHN'S DISEASE PATIENTS
OCCURRENCE OF COLORECTAL CANCER AND THE EFFECT OF MEDICAL TREATMENT IN CROHN'S DISEASE PATIENTS

IBD (Posters)  et al.

PHYSICIAN PREFERENCES FOR BIOLOGICS FOR THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN FRANCE, GERMANY AND THE UNITED KINGDOM
PHYSICIAN PREFERENCES FOR BIOLOGICS FOR THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN FRANCE, GERMANY AND THE UNITED KINGDOM

IBD (Posters)  et al.

ASSESSMENT OF VEDOLIZUMAB DISEASE-DRUG-DRUG INTERACTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
ASSESSMENT OF VEDOLIZUMAB DISEASE-DRUG-DRUG INTERACTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

IBD (Posters)  et al.

EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 TRIAL
EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 TRIAL

IBD (Posters)  et al.

VEDOLIZUMAB ACHIEVES CORTICOSTEROID-FREE CLINICAL RESPONSE AND REMISSION IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD META-ANALYSIS
VEDOLIZUMAB ACHIEVES CORTICOSTEROID-FREE CLINICAL RESPONSE AND REMISSION IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD META-ANALYSIS

IBD (Posters)  et al.

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

IBD (Posters)  et al.

REAL-WORLD EVIDENCE OF VEDOLIZUMAB ACHIEVING MUCOSAL HEALING AND ENDOSCOPIC IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS
REAL-WORLD EVIDENCE OF VEDOLIZUMAB ACHIEVING MUCOSAL HEALING AND ENDOSCOPIC IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

EXPOSURE TO AN INFLAMMATORY MIX RE-INDUCES INFLAMMATION IN ORGANOIDS OF ULCERATIVE COLITIS PATIENTS, INDEPENDENT OF THE INFLAMMATORY STATE OF THE TISSUE OF ORIGIN
EXPOSURE TO AN INFLAMMATORY MIX RE-INDUCES INFLAMMATION IN ORGANOIDS OF ULCERATIVE COLITIS PATIENTS, INDEPENDENT OF THE INFLAMMATORY STATE OF THE TISSUE OF ORIGIN

IBD (Posters)  et al.

RISK OF PROGRESSION OF PRECLINICAL ULCERATIVE COLITIS
RISK OF PROGRESSION OF PRECLINICAL ULCERATIVE COLITIS

IBD (Posters)  et al.

GASTROINTESTINAL ULTRASOUND PERFORMED ON ADMISSION PREDICTS THE NEED FOR INPATIENT INFLIXIMAB THERAPY IN HOSPITALISED ULCERATIVE COLITIS PATIENTS
GASTROINTESTINAL ULTRASOUND PERFORMED ON ADMISSION PREDICTS THE NEED FOR INPATIENT INFLIXIMAB THERAPY IN HOSPITALISED ULCERATIVE COLITIS PATIENTS

IBD (Posters)  et al.

WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS
WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS

IBD (Posters)  et al.

Item 301 - 320 / 558
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
16
17 18 19 20 21 22 23 24 25 26 27 28